Abevmy 400mg (mylan) | Bevacizumab | MHP

ABEVMY 400MG/16ML

NON-SQUAMOUS

DESCRIPTION

Bevacizumab is a drug sold under the name of Abevmy 400mg and which is categorized as monoclonal anti-body & anti-angiogenesis When Abevmy 400mg concomitant use with human monoclonal antibody IgG1, that circumstance and prohibits the biological action of human vascular endothelial growth factor (VEGF).

USAGE

Abevmy 100mg is indicated for the treatment of some of the conditions like :

Metastatic colon or rectal cancer 

Non-squamous, non-small cell lung cancer 

Glioblastoma 

Metastatic renal cell cancer 

Metastatic cervical cancer

Epithelial ovarian, fallopian tube or peritoneal cancer.

MECHANISM OF ACTION

Abevmy 400mg Injection comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells

This interaction prevents endothelial cell multiplication and new blood vessel production occurs

Hence in counts cessation of metastatic cancer cells development happens

Brand : Abevmy
Ingredients : Bevacizumab
Strength : 400mg/16ml
Manufactured : Mylan Pharmaceuticals
Package : 4ml in a 1 vial

DISTRIBUTION

The volume of distribution is 2.9 (22%) L

ELIMINATION

The Bevacizumab half-life period is 20days (11 to 50days)

DOSAGE MANAGEMENT

Key point:

Avoid administration of Abevmy 400mg Injection before at least 28 days following surgery and the wound is completely cured 

colorectal carcinoma: 

Concomitant use with 5-fluorouracil based chemotherapy is the usual dosage of Abevmy: While concomitant use with bolus IFL the dose is 5mg/kg of Abevmy for every 2 weeks IV. 

While in combination with FOLFOX4 the dose is 10mg/kg of Abevmy for every 2 weeks IV 

5mg/kg IV Abevmy for every 2 weeks or 7.5 mg/kg Abevmy as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy 

Non-small cell lung cancer:

While combining with carboplatin and paclitaxel: The Abevmy usual dosage is 15mg/kg IV for every 3 weeks by

Glioblastoma: 

For every 2 weeks: 10mg/kg of Abevmy 400mg Injection administered IV 

Metastatic renal cell cancer: 

Concurrent use with interferon alfa: The Abevmy usual dosage is 10mg/kg IV for every 2 weeks 

Metastatic cervical cancer: 

Combining with paclitaxel and cisplatin or with paclitaxel and topotecan: The drug Abevmy usual dosage is 15mg/kg of Abevmy given intravenously for every 3 weeks 

Epithelial ovarian, fallopian tube or peritoneal cancer:

Platinum opposing:

Concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan: The Abevmy regular dosage is 10mg/kg of Abevmy for every 2 weeks 

Or Combining with topotecan: The Abevmy regular dosage 15mg/kg of Abevmy given through IV for every 3 weeks

Platinum responsive:

concomitant with carboplatin and paclitaxel for 6 to 8 cycles: The drug Abevmy recommended dosage of is 15mg/kg given IV for 3 weeks 

Combining with gemcitabine & carboplatin for 6 to 10 cycles: The Abevmy recommended dosage is 15mg/kg of Abevmy given IV for 3 weeks 

Preparation & administration:

Abevmy is intravenous solution

At initial infusion:

given IV infusion over 90 minutes

Following infusions:

give second infusion over 60 minutes, if tolerated

Administer all following infusion over 30minutes

Abevmy IV infusion is prepared in aseptic condition

Abevmy 400mg containing 16ml solution whereas 100mg containing 4ml

Abevmy dilute into 100ml of 0.9% NS

Do not dilute with dextrose solution

Dispose the remaining portion of medicine which is left in a vial.

FOR MORE INFO

CONTACT NO : +91-9940472902

EMAIL : millionhealthpharmaceuticals@gmail.com

WEBSITE URL : https://millionpharma.com/abevmy-400mg.php